Alloplex Biotherapeutics
Boston, US · 1 known investors
Alloplex Biotherapeutics develops SUPLEXA, a non-genetically engineered autologous cellular therapy for treating solid tumors and autoimmunity by retraining patients' immune cells. The company's ENLYST platform reprograms activated immune cells using natural signals and has completed a Phase 1 clinical trial demonstrating safety and clinical activity across multiple tumor types.
BiotechHealthtechMedical Devices
Founders & leadership
FB
Frank BorrielloMD, PhD